# Cullinan (CGEM) — News

CGEM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cgem/news

## Recent headlines

- [Cullinan Therapeutics - Expects phase 1 CLN-049 study update in December](https://www.ainvest.com/news/cullinan-therapeutics-expects-phase-1-cln-049-study-update-december-2610) — AInvest Wire, Oct 8, 2026
  Cullinan Therapeutics is preparing to release updated data from the Phase 1 dose-escalation study of its FLT3×CD3 bispecific T-cell engager, CLN-049, in the fourth quarter of 2026. The therapy is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) and has already…
- [Cullinan Therapeutics announces first patient dosed in planned registrational phase 2 study of CLN-049 in relapsed/refractory acute myeloid leukemia](https://www.ainvest.com/news/cullinan-therapeutics-announces-patient-dosed-planned-registrational-phase-2-study-cln-049-relapsed-refractory-acute-myeloid-leukemia-2610) — AInvest Wire, Oct 8, 2026
  Cullinan Therapeutics has announced that the first patient has been dosed in a planned registrational phase 2 study of CLN-049 for the treatment of relapsed or refractory AML . This milestone marks a key step in the company’s clinical development strategy for the investigational therapy. The phase…
- [Petra Diamonds - Appoints Questco corporate advisory to manage strategic review](https://www.ainvest.com/news/petra-diamonds-appoints-questco-corporate-advisory-manage-strategic-review-2610) — AInvest Wire, Oct 5, 2026
  Petra Diamonds Limited has announced the appointment of Questco Corporate Advisory to conduct a strategic review of the company’s operations and future direction. This decision follows ongoing efforts to refine the company’s business strategy and enhance operational efficiency, particularly in…
- [OTSUKA: Zipalertinib plus chemo shows 6-mth median PFS benefit](https://www.ainvest.com/news/otsuka-zipalertinib-chemo-shows-6-mth-median-pfs-benefit-2609) — AInvest Wire, Sep 13, 2026
  Article: A clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy in the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations has demonstrated statistically significant improvement in…
- [Cullinan Therapeutics shares reverse premarket course; last down 4.2%](https://www.ainvest.com/news/cullinan-therapeutics-shares-reverse-premarket-4-2-2608) — AInvest Wire, Aug 13, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).